| DHR |
Report |
Core revenue growth |
BEAT |
pred ~2.5% vs. cons 2.0% |
MEDIUM |
| DHR |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.88 vs. cons $1.84 |
MEDIUM |
| DHR |
Report |
Adjusted operating margin |
IN-LINE |
pred ~26.7% vs. cons 26.6% |
MEDIUM |
| DHR |
Guide |
FY26 core revenue growth |
UNCHANGED |
guide ~3.0%-6.0% vs. cons 3.5% (FY26) |
MEDIUM |
| DHR |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$8.45 midpoint vs. cons $8.46 (FY26) |
MEDIUM |
| DHR |
Guide |
4Q26 core-growth exit rate |
UNCHANGED |
guide ~5.0% vs. cons 5.0% (4Q26) |
MEDIUM |
| DHR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| DHR |
Return |
5-day cumulative residual |
+1.5% (FADE) |
A modest 2Q core-growth and EPS beat should produce an initial positive reaction, but unchanged FY26 core-growth and EPS guidance leaves out-period estimates near ~$8.46 versus a ~$8.45 guide midpoint; without a higher 2H/4Q bridge, the initial ~+2.5% residual move is likely to fade toward ~+1.5% by day five. |
MEDIUM |